Gene therapy · developed by Sarepta Therapeutics
SRP-9004 is an agent given by intravenous infusion, studied in limb girdle muscular dystrophy type 2D/R3.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06747273 | Phase 1 | Limb Girdle Muscular Dystrophy | Terminated | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Limb Girdle Muscular DystrophyLimb Girdle Muscular Dystrophy Type 2D/R3
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →